You are here

Step 5: Effective Drug Treatment of HIV

Active Resources: 15

Archive Resources: 11

  • This toolkit provides different assessment tools and guides to assist in addressing common health literacy issues in clinical care systems.  The following are included in this CDC toolkit:

    Type: Clinical Reference Tools
    Publish Date: 2/2/2016
  • 36 evidence-based recommendations are provided for interventions to optimize the HIV care environment; increase HIV testing and linkage to care, treatment coverage, retention in care, and vira

    Type: Guidelines
    Publish Date: 11/9/2015
  • Illustrates how improving patient self-management can help to reduce gaps along the HIV care continuum.

    Type: Clinical Reference Tools
    Publish Date: 7/1/2015
    Review Date: 5/18/2021
  • This toolkit was developed for use for members of the  AETC Program and HIV health care professionals  to serve as a resource guide on HIV and aging.

    Type: Clinical Reference Tools
    Publish Date: 4/29/2015
  • This infographic is a snapshot of how AETC NRC activities support and embrace the expertise of the broader AETC community and other national organizations.

    Type: Clinical Reference Tools
    Publish Date: 8/22/2014
  • The HIV/AIDS Bureau (HAB) of HRSA has developed a series of clinical performance indicators for Ryan White HIV/AIDS

    Type: Clinical Reference Tools
    Publish Date: 7/31/2014
    Review Date: 2/12/2018
  • This video describes HIV viral replication and where antiretroviral drugs work in the replication process.

    Type: Online and Self-Paced Learning
    Publish Date: 7/17/2014
  • Patient education video discusses basic information about HIV infection, lab values, and the importance of adherence to ART regimen.

    Type: Clinical Reference Tools
    Publish Date: 7/7/2014
    Review Date: 5/8/2019
  • Pocket reference with interaction information and patient education recommendations. Order printed copies online from the NY/NJ AETC.

    Type: Clinical Reference Tools
    Publish Date: 2/1/2014
  • The 69 slides on Occupational Exposure to HIV, HCV, and HBV provide an overview of basic HIV information as well as fulfill the following objectives:

    Type: Training Materials
    Publish Date: 1/15/2014
  • The AETC Program national, regional, and local partners are a part of the HRSA-funded Ryan White HIV/AIDS Program.

    Type: Clinical Reference Tools
    Publish Date: 6/1/2013
    Review Date: 1/11/2017

Articles: 5

  • Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)

    Jennifer Cocohoba's picture

    Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...

  • Ibalizumab Approved for Persons with Multidrug Resistant HIV

    Susa Coffey's picture

    Ibalizumab (TNX-355), an entry inhibitor, has been approved by the FDA for use in persons with an extensive ARV treatment history and multidrug resistant HIV who are on a failing ARV regimen. Ibalizumab (trade name: Trogarzo) is a monoclonal antibody that binds the CD4 receptor and blocks HIV...

  • CROI 2017: Failure of Dolutegravir Monotherapy

    Susa Coffey's picture

    Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...

  • Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

    Jennifer Cocohoba's picture

    Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...

  • Switching from TDF/FTC to TAF/FTC

    Susa Coffey's picture

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...